- Home
- NRXS vs COSM Comparison
NRXS vs COSM Comparison
Compare NRXS & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- COSM
- Stock Information
- Founded
- NRXS 2011
- COSM 2009
- Country
- NRXS United States
- COSM United States
- Employees
- NRXS N/A
- COSM N/A
- Industry
- NRXS
- COSM Other Pharmaceuticals
- Sector
- NRXS
- COSM Health Care
- Exchange
- NRXS Nasdaq
- COSM Nasdaq
- Market Cap
- NRXS 17.8M
- COSM 18.4M
- IPO Year
- NRXS 2023
- COSM 2013
- Fundamental
- Price
- NRXS $2.31
- COSM $0.62
- Analyst Decision
- NRXS
- COSM
- Analyst Count
- NRXS 0
- COSM 0
- Target Price
- NRXS N/A
- COSM N/A
- AVG Volume (30 Days)
- NRXS 22.4K
- COSM 397.6K
- Earning Date
- NRXS 04-08-2025
- COSM 11-14-2024
- Dividend Yield
- NRXS N/A
- COSM N/A
- EPS Growth
- NRXS N/A
- COSM N/A
- EPS
- NRXS N/A
- COSM N/A
- Revenue
- NRXS $2,456,219.00
- COSM $56,042,109.00
- Revenue This Year
- NRXS $383.16
- COSM $4.53
- Revenue Next Year
- NRXS N/A
- COSM $25.00
- P/E Ratio
- NRXS N/A
- COSM N/A
- Revenue Growth
- NRXS N/A
- COSM 13.01
- 52 Week Low
- NRXS $2.05
- COSM $0.47
- 52 Week High
- NRXS $3.78
- COSM $1.58
- Technical
- Relative Strength Index (RSI)
- NRXS 38.24
- COSM 40.41
- Support Level
- NRXS $2.39
- COSM $0.60
- Resistance Level
- NRXS $2.51
- COSM $0.67
- Average True Range (ATR)
- NRXS 0.15
- COSM 0.07
- MACD
- NRXS -0.03
- COSM -0.01
- Stochastic Oscillator
- NRXS 7.14
- COSM 6.77
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.